

From the Chief Pharmaceutical Officer
Professor Cathy Harrison



FOR ACTION

Chief Operating Officer, Strategic Planning and Performance Group (*for onward transmission to relevant staff*)

Chief Executive, Business Services Organisation (*for onward transmission to relevant staff*)

Assistant Director of Integrated Care, Head of Pharmacy and Medicines Management, SPPG (*for onward distribution to Community Pharmacies*).

Head of General Medical Services, SPPG (*for onward distribution to GP Practices*)

GP Medical Advisers, Strategic Planning and Performance Group.

Castle Buildings
Stormont
BELFAST
BT4 3SQ
Tel: 028 90 523219
Email: cathy.harrison@health-ni.gov.uk

Date: 19 January 2026

Dear Colleagues,

**SERIOUS SHORTAGE PROTOCOL WITHDRAWAL – FIXAPOST®
(LATANOPROST 50MCG/ML / TIMOLOL 5MG/ML) 0.2ML UNIT DOSE
PRESERVATIVE FREE EYE DROPS**


Serious shortage protocols (SSPs) under the Human Medicines Regulations 2012 (HMRs) are an additional tool to manage and mitigate medicines shortages. An SSP enables community pharmacists to supply a specified medicine in accordance with a protocol rather than a prescription, without needing to seek authorisation from the prescriber, saving time for patients, pharmacists and prescribers. They are used in the case of a serious shortage, where a medicine would be likely to be out of stock for some time, and if, in the opinion of ministers, it would help manage the supply situation.

I am writing to inform you that the Department of Health and Social Care (DHSC) has confirmed that the supply situation regarding the availability of the alternative product, Vizilatan® Duo, listed under **SSP086** to be supplied for **Fixapost® (latanoprost 50 mcg/ml / timolol 5mg/ml) 0.2ml unit dose preservative free eye drops** can no longer support the additional demand. Consequently, **SSP086** which was due to expire on Friday 6 February 2026 is being withdrawn and will now expire on **Friday 23 January 2026**.

Action Required

All relevant staff should be made aware of this SSP withdrawal. I would ask the SPPG to bring this information to the attention of GP Practices and Community Pharmacists directly.

Yours sincerely,

A handwritten signature in black ink, appearing to read "Cathy Harrison". The signature is written in a cursive style with a long horizontal stroke at the end.

Professor Cathy Harrison
Chief Pharmaceutical Officer